Analyst consensus rating
Quince Therapeutics Analyst Rating: Buy
QNCX is rated Buy by 5 analysts with a $77.20 target. As of 2026-08-27.
Direct answer
Quince Therapeutics's consensus rating is Buy.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $77.20.
Forecast evidence checked August 27, 2026.
Get free Quince Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $31.31
- Average price target
- $77.20
- High price target
- $98.00
- Low price target
- $68.00
- Low target gap
- +117.2%
- Target upside
- +146.6%
- High target gap
- +213%
- Target range width
- 95.8%
- Consensus rating
- Buy
- Analysts
- 5
- Evidence date
- August 27, 2026
- Valid through
- September 3, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Quince Therapeutics?
Quince Therapeutics has a verified Buy consensus. The same dataset has an average price target of $77.20.
How far are Quince Therapeutics's low and high targets from the recorded price?
The low target implies +117.2%, while the high target implies +213%.
How many analysts are included in Quince Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Quince Therapeutics's target upside or downside calculated?
The average target of $77.20 is divided by the recorded price of $31.31, then one is subtracted to produce +146.6%. This does not guarantee a future return.
When was Quince Therapeutics's analyst forecast verified?
The data was verified on 2026-08-27. The dataset is valid through 2026-09-03.